v::ALK
About
Gene context: ALK
Biomarker Type: Rearrangement
Present: True
Rearrangement Type: Fusion
Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
Therapeutic response
Precision oncology relationships for therapeutic response involving this biomarker.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (2) HC (1) | v::ALK | Non-Small Cell Lung Cancer | Alectinib | |
| FDA (1) | v::ALK | Non-Small Cell Lung Cancer | Atezolizumab | |
| FDA (1) HC (1) | v::ALK | Non-Small Cell Lung Cancer | Brigatinib | |
| FDA (1) HC (2) | v::ALK | Non-Small Cell Lung Cancer | Ceritinib | |
| FDA (1) HC (1) | v::ALK | Non-Small Cell Lung Cancer | Crizotinib | |
| FDA (1) | v::ALK | Anaplastic Large Cell Lymphoma | Crizotinib | |
| FDA (1) | v::ALK | Inflammatory Myofibroblastic Tumor | Crizotinib | |
| FDA (1) HC (2) | v::ALK | Non-Small Cell Lung Cancer | Lorlatinib | |
| FDA (1) | v::ALK | Non-Small Cell Lung Cancer | Ensartinib |